Search

536 Result(s)
Sort by

PRRS vaccine discovery for swine

PRRS vaccine discovery for swine

PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
“Rare diseases are quite common”

“Rare diseases are quite common”

Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
Targeting Tumor Stroma

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Results for Jardiance EMPACT-MI phase III trial

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
We nurture innovative ideas

We nurture innovative ideas

At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.
History video

History video

Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
Our partners university of georgia

Our partners university of georgia

We're partnering with the University of Georgia to address unmet needs and find solutions to some of the biggest challenges in animal health.
Newsbits

Newsbits

Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
Lyon

Lyon

The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.